GGHC
KDNY

Gilder Gagnon Howe & Co’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,213
Closed -$874K – 261
2015
Q4 		$874K Sell
6,213
-225
-3% -$30.6K 0.01% 180
2015
Q3 		$624K Sell
6,438
-58,134
-90% -$6.92M 0.01% 199
2015
Q2 		$9.79M Buy
+64,572
New +$10.7M 0.13% 120

Other funds holding KDNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Gilder Gagnon Howe & Co's KDNY Position: Q1 2016 in Review

Gilder Gagnon Howe & Co sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2016, closing a stake of 6,213 shares — an estimated $874K sold.

Gilder Gagnon Howe & Co first reported a position in KDNY in Q2 2015 and held it in 3 quarters. The position peaked at $9.79M in Q2 2015. 89 funds tracked by Wall St. Rank hold KDNY as of Q1 2016.

  • Gilder Gagnon Howe & Co reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 6,213 Chinook Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $874K.
  • Gilder Gagnon Howe & Co first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Chinook Therapeutics, Inc. Common Stock position peaked at $9.79M in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2016, filed 3 May 2016.